Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2017-002979-26 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a randomized, open-label, multi-center, global, phase III study to determine the efficacy and safety of Durvalumab + BCG combination therapy in the treatment of patients with non-muscle-invasive bladder cancer
Patients will be randomized in a 1:1:1 ratio to receive treatment with Durvalumab + BCG combination therapies, or Standard of Care (SoC) therapy.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Durvalumab plus BCG (induction + maintenance) | Experimental | Durvalumab (MEDI4736) plus Bacillus Calmette-Guerrin (BCG) combination therapy |
|
| Durvalumab plus BCG (induction only) | Experimental | Durvalumab (MEDI4736) plus Bacillus Calmette-Guerrin (BCG) combination therapy |
|
| BCG treatment (Standard of care therapy) | Active Comparator | Bacillus Calmette-Guerrin (BCG) standard of care treatment |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Durvalumab (MEDI4736) | Biological | Investigational product |
|
| Measure | Description | Time Frame |
|---|---|---|
| The efficacy of Durvalumab + BCG (induction plus maintenance) combination therapy compared to SoC in terms of Disease free survival (DFS) in patients with NMIBC | Disease-free survival using Investigator disease assessments. | Up to 4 years |
| Measure | Description | Time Frame |
|---|---|---|
| To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to BCG (induction and maintenance) alone in terms of DFS 24 months | Proportion of patients alive and disease free at 24 months using Investigator disease assessments. DFS24 is defined as the proportion of patients alive and disease-free at 24 months after randomization, per Investigator disease assessment. |
Not provided
Inclusion Criteria: For inclusion in the study, patients should fulfill the following criteria:
Aged at least 18 years
BCG-naïve (patients who have not received prior intravesical BCG or who previously received but stopped BCG more than 3 years before study entry are eligible)
Local histological confirmation (based on pathology report) of high-risk transitional cell carcinoma of the urothelium of the urinary bladder confined to the mucosa or submucosa. A high risk tumor is defined as one of the following
Complete resection of all Ta/T1 papillary disease prior to randomization, with the TURBT removing high-risk NMIBC performed not more than 4 months before randomization in the study. Patients with residual CIS after TURBT are eligible
No prior radiotherapy for bladder cancer
No prior exposure to immune-mediated therapy of cancer including, but not limited to, other anti CTLA-4, anti-PD-1, anti-PD-L1, and anti-programmed cell death ligand 2 antibodies. Patients who have been treated with anticancer vaccines will be excluded
Exclusion Criteria:
Patients should not enter the study if any of the following exclusion criteria are fulfilled:
Evidence of muscle-invasive, locally advanced, metastatic, and/or extra vesical bladder cancer (ie, T2, T3, T4, and / or stage IV)
Concurrent extravesical (ie, urethra, ureter, or renal pelvis), non-muscle-invasive transitional cell carcinoma of the urothelium
Previous investigational product (IP) assignment in the present study
Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for noncancer related conditions (eg, hormone replacement therapy) is acceptable. Chemotherapy for previous instances of NMIBC is acceptable.
Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:
History of another primary malignancy except for
Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Auchenflower | 4066 | Australia | |||
| Research Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41115436 | Derived | De Santis M, Palou Redorta J, Nishiyama H, Krawczynski M, Seyitkuliev A, Novikov A, Guerrero-Ramos F, Zukov R, Kato M, Kawahara T, Goeman L, Puente J, Hellmis E, Powles T, Radziszewski P, Gust KM, Vasey P, Bigot P, Fradet Y, Hunting J, Armstrong J, Boulos S, Hois S, Shore ND; POTOMAC Investigators. Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. Lancet. 2025 Nov 8;406(10516):2221-2234. doi: 10.1016/S0140-6736(25)01897-5. Epub 2025 Oct 17. |
Not provided
Not provided
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Not provided
Not provided
Not provided
Not provided
Not provided
| Bacillus Calmette-Guerin (BCG) | Biological | Standard of care |
|
| Up to 4 years |
| To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to BCG (induction and maintenance) alone in terms of OS5 | Overall survival at 5 years. Overall survival (OS) is defined as the time from the date of randomization until death due to any cause regardless of whether the patient withdraws from randomized therapy or receives another anti-cancer therapy (i.e. date of death or censoring - date of randomization +1). Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive | Up to 7 years |
| To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to BCG (induction and maintenance) alone in terms of any disease-free survival | Any disease-free survival using Investigator disease assessments. Any disease-free survival (aDFS) is defined similarly as DFS, except that aDFS includes recurrence of low/medium risk NMIBC. This will be based on Investigator disease assessments. | Up to 7 years |
| To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to BCG (induction and maintenance) alone in terms of Time to MIBC and/or Metastatic Disease | Time to MIBC and/or metastatic disease using Investigator disease assessments. Time to MIBC and/or metastatic disease is defined as the time from the date of randomization until the date of first documented MIBC and/or metastatic disease as assessed by Investigator. Time to MIBC and/or metastatic disease does not include deaths. If patients died without MIBC and/or metastatic disease, they will be censored at the time of death. All other censoring rules per DFS analysis will be applied including censoring patients with an event after 2 missed visits and patients with no evaluable disease assessments or no baseline data. | Up to 4 years |
| To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to BCG (induction and maintenance) alone with respect to time to cystectomy | Time to cystectomy using Investigator disease assessments. Time to cystectomy is defined as the time from the date of randomization until the date of cystectomy as reported by Investigator. Patients who died prior to cystectomy will be censored at the time of death. Patients who have not had a cystectomy at the time of analysis will be censored at the last recorded date on which the patient was known to be alive. No other censoring rules per the DFS analysis will be applied. | Up to 4 years |
| To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to BCG (induction and maintenance) alone in terms of time to development of upper tract urothelial carcinoma | Time to development of upper tract urothelial carcinoma using Investigator disease assessments. Time to development of upper tract urothelial carcinoma (TTUTUC) is defined as the time from the date of randomization until the date of development of upper tract urothelial carcinoma as assessed by Investigator using CT urography or ureteroscopy (less common). TTUTUC does not include deaths. Patients who died without upper tract urothelial carcinoma will be censored at the time of death. Other censoring rules per DFS analysis will be applied, including censoring patients with no baseline data but excluding censoring patients with an event after 2 missed visits as evaluation of the upper urinary tract is not part of regular disease assessment and is performed as clinically indicated. | Up to 7 years |
| To assess the efficacy of durvalumab + BCG (induction only) combination therapy compared to BCG (induction and maintenance) alone in terms of Disease-free survival | Any disease-free survival (aDFS) is defined similarly as DFS, except that aDFS includes recurrence of low/medium risk NMIBC. This will be based on Investigator disease assessments. | Up to 7 years |
| To assess the efficacy of durvalumab + BCG (induction only) combination therapy compared to BCG (induction and maintenance) alone in terms of patients alive and disease free at 24 months | Proportion of patients alive and disease free at 24 months using Investigator disease assessments. DFS24 is defined as the proportion of patients alive and disease-free at 24 months after randomization, per Investigator disease assessment | Up to 24 months |
| To assess the efficacy of durvalumab + BCG (induction only) combination therapy compared to BCG (induction and maintenance) alone in terms of OS5 | Overall survival at 5 years. Overall survival (OS) is defined as the time from the date of randomization until death due to any cause regardless of whether the patient withdraws from randomized therapy or receives another anti-cancer therapy (i.e. date of death or censoring - date of randomization +1). | up to 5 years |
| To assess the efficacy of durvalumab + BCG (induction only) combination therapy compared to BCG (induction and maintenance) alone in terms of any disease-free survival | Any disease-free survival using Investigator disease assessments. Any disease-free survival (aDFS) is defined similarly as DFS, except that aDFS includes recurrence of low/medium risk NMIBC. This will be based on Investigator disease assessments. | Up to 7 years |
| To assess the efficacy of durvalumab + BCG (induction only) combination therapy compared to BCG (induction and maintenance) alone in terms of Time to MIBC and/or metastatic disease | Time to MIBC and/or metastatic disease using Investigator disease assessments. Time to MIBC and/or metastatic disease is defined as the time from the date of randomization until the date of first documented MIBC and/or metastatic disease as assessed by Investigator. Time to MIBC and/or metastatic disease does not include deaths. If patients died without MIBC and/or metastatic disease, they will be censored at the time of death. All other censoring rules per DFS analysis will be applied including censoring patients with an event after 2 missed visits and patients with no evaluable disease assessments or no baseline data. | Up to 7 years |
| To assess the efficacy of durvalumab + BCG (induction only) combination therapy compared to BCG (induction and maintenance) alone in terms of time to cystectomy | Time to cystectomy using Investigator disease assessments. Time to cystectomy is defined as the time from the date of randomization until the date of cystectomy as reported by Investigator. Patients who died prior to cystectomy will be censored at the time of death. Patients who have not had a cystectomy at the time of analysis will be censored at the last recorded date on which the patient was known to be alive. No other censoring rules per the DFS analysis will be applied. | Up to 7 years |
| To assess the efficacy of durvalumab + BCG (induction only) combination therapy compared to BCG (induction and maintenance) alone time to development of upper tract urothelial carcinoma | Time to development of upper tract urothelial carcinoma using Investigator disease assessments. Time to development of upper tract urothelial carcinoma (TTUTUC) is defined as the time from the date of randomization until the date of development of upper tract urothelial carcinoma as assessed by Investigator using CT urography or ureteroscopy (less common). TTUTUC does not include deaths. Patients who died without upper tract urothelial carcinoma will be censored at the time of death. Other censoring rules per DFS analysis will be applied, including censoring patients with no baseline data but excluding censoring patients with an event after 2 missed visits as evaluation of the upper urinary tract is not part of regular disease assessment and is performed as clinically indicated. | Up to 7 years |
| To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to durvalumab + BCG (induction only) in terms of Disease-free survival | Disease-free survival using Investigator disease assessments.Any disease-free survival (aDFS) is defined similarly as DFS, except that aDFS includes recurrence of low/medium risk NMIBC. This will be based on Investigator disease assessments. | Up to 4 years |
| To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to durvalumab + BCG (induction only) in terms of Proportion of patients alive and disease free at 24 months | Proportion of patients alive and disease free at 24 months using Investigator disease assessments. DFS24 is defined as the proportion of patients alive and disease-free at 24 months after randomization, per Investigator disease assessment. | Up to 24 months |
| To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to durvalumab + BCG (induction only) in terms of Overall survival at 5 years | Overall survival (OS) is defined as the time from the date of randomization until death due to any cause regardless of whether the patient withdraws from randomized therapy or receives another anti-cancer therapy (i.e. date of death or censoring - date of randomization +1). The proportion of patients alive at 5 years (OS5) | Up to 7 years |
| To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to durvalumab + BCG (induction only) in terms of any disease-free survival | Any disease-free survival using Investigator disease assessments. Any disease-free survival (aDFS) is defined similarly as DFS, except that aDFS includes recurrence of low/medium risk NMIBC. This will be based on Investigator disease assessments. | up to 5 years |
| To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to durvalumab + BCG (induction only) in terms of time to MIBC and/or metastatic disease | Time to MIBC and/or metastatic disease using Investigator disease assessments. Time to MIBC and/or metastatic disease is defined as the time from the date of randomization until the date of first documented MIBC and/or metastatic disease as assessed by Investigator. Time to MIBC and/or metastatic disease does not include deaths. If patients died without MIBC and/or metastatic disease, they will be censored at the time of death. All other censoring rules per DFS analysis will be applied including censoring patients with an event after 2 missed visits and patients with no evaluable disease assessments or no baseline data. | up to 5 yeas |
| To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to durvalumab + BCG (induction only) in terms of time to cystectomy | Time to cystectomy using Investigator disease assessments. Time to cystectomy is defined as the time from the date of randomization until the date of cystectomy as reported by Investigator. Patients who died prior to cystectomy will be censored at the time of death. Patients who have not had a cystectomy at the time of analysis will be censored at the last recorded date on which the patient was known to be alive. No other censoring rules per the DFS analysis will be applied. | up to 5 years |
| To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to durvalumab + BCG (induction only) in terms of Time to development of upper tract urothelial carcinoma | Time to development of upper tract urothelial carcinoma using Investigator disease assessments. Time to development of upper tract urothelial carcinoma (TTUTUC) is defined as the time from the date of randomization until the date of development of upper tract urothelial carcinoma as assessed by Investigator using CT urography or ureteroscopy (less common). TTUTUC does not include deaths. Patients who died without upper tract urothelial carcinoma will be censored at the time of death. Other censoring rules per DFS analysis will be applied, including censoring patients with no baseline data but excluding censoring patients with an event after 2 missed visits as evaluation of the upper urinary tract is not part of regular disease assessment and is performed as clinically indicated. | up to 5 years |
| Complete response rate (CRR) at 6 months using Investigator disease assessments | To assess the efficacy of durvalumab + BCG combination therapy compared to BCG (induction and maintenance) for patients with CIS prior to study entry or at baseline cystoscopy. | up to 6 months |
| EORTC QLQ-C30 and EORTC QLQ-NMIBC24 | To assess disease-related symptoms and HRQoL in patients with NMIBC treated with durvalumab + BCG (induction and maintenance) combination therapy and durvalumab + BCG (induction only) combination therapy compared to BCG (induction and maintenance) alone and compared to each other using the EORTC QLQ-C30 questionnaire and the EORTC QLQ-NMIBC24 questionnaire | up to 5 years |
| PRO version of the CTCAE with approximately 19 items (PRO-CTCAE) symptoms in countries where language is available | To assess patient-reported treatment tolerability directly using specific PRO-CTCAE symptoms | up to 5 years |
| PK serum concentration of durvalumab | To assess the PK of durvalumab when used in combination with BCG treatment | up to 5 years |
| Presence of ADAs for durvalumab | To investigate the immunogenicity of durvalumab when used in combination with BCG treatment | up to 5 years |
| Box Hill |
| 3128 |
| Australia |
| Research Site | Brisbane | 4122 | Australia |
| Research Site | Kogarah | 2217 | Australia |
| Research Site | Orange | 2800 | Australia |
| Research Site | Parkville | 3000 | Australia |
| Research Site | Westmead | 2145 | Australia |
| Research Site | Wollongong | 2500 | Australia |
| Research Site | Graz | 8036 | Austria |
| Research Site | Innsbruck | 6020 | Austria |
| Research Site | Linz | 4020 | Austria |
| Research Site | Salzburg | 5020 | Austria |
| Research Site | Vienna | 1090 | Austria |
| Research Site | Brussels | 1070 | Belgium |
| Research Site | Ghent | 9000 | Belgium |
| Research Site | Leuven | 3000 | Belgium |
| Research Site | Roeselare | 8800 | Belgium |
| Research Site | Kingston | Ontario | K7L 3J7 | Canada |
| Research Site | Toronto | Ontario | M5G 2M9 | Canada |
| Research Site | Chicoutimi | Quebec | G7H 5H6 | Canada |
| Research Site | Montreal | Quebec | H2X 3E4 | Canada |
| Research Site | Québec | Quebec | G1J 1Z4 | Canada |
| Research Site | Amiens | 80054 | France |
| Research Site | Angers | 49033 | France |
| Research Site | Bordeaux | 33076 | France |
| Research Site | Lyon | 69437 | France |
| Research Site | Marseille | 13003 | France |
| Research Site | Montpellier | 34295 | France |
| Research Site | Strasbourg | 67098 | France |
| Research Site | Suresnes | 92151 | France |
| Research Site | Berlin | 10117 | Germany |
| Research Site | Cologne | 50968 | Germany |
| Research Site | Duisburg | 47169 | Germany |
| Research Site | Hanover | 30625 | Germany |
| Research Site | Heidelberg | 69120 | Germany |
| Research Site | Marburg | 35043 | Germany |
| Research Site | Mettmann | 40822 | Germany |
| Research Site | Mühlheim An Der Ruhr | 45468 | Germany |
| Research Site | München | 81377 | Germany |
| Research Site | Münster | 48149 | Germany |
| Research Site | Nürtingen | 72622 | Germany |
| Research Site | Wesel | 46483 | Germany |
| Research Site | Würselen | 52146 | Germany |
| Research Site | Zirndorf | 90513 | Germany |
| Research Site | Bunkyō City | 113-8603 | Japan |
| Research Site | Fukuoka | 812-8582 | Japan |
| Research Site | Hirosaki-shi | 036-8563 | Japan |
| Research Site | Kanazawa | 920-8641 | Japan |
| Research Site | Kita-gun | 761-0793 | Japan |
| Research Site | Koshigaya-shi | 343-8555 | Japan |
| Research Site | Kōtoku | 135-8550 | Japan |
| Research Site | Matsuyama | 791-0280 | Japan |
| Research Site | Miyazaki | 889-1692 | Japan |
| Research Site | Nagasaki | 852-8501 | Japan |
| Research Site | Nagoya | 467-0001 | Japan |
| Research Site | Okayama | 700-8558 | Japan |
| Research Site | Osaka | 541-8567 | Japan |
| Research Site | Osaka | 545-8586 | Japan |
| Research Site | Osakasayama-shi | 589-8511 | Japan |
| Research Site | Sapporo | 060-8543 | Japan |
| Research Site | Shinjuku-ku | 160-8582 | Japan |
| Research Site | Toyama | 930-0194 | Japan |
| Research Site | Tsukuba | 305-8576 | Japan |
| Research Site | Yokohama | 232-0024 | Japan |
| Research Site | Amsterdam | 1081 HV | Netherlands |
| Research Site | Breda | 4818 CK | Netherlands |
| Research Site | Utrecht | 3543 AZ | Netherlands |
| Research Site | Bialystok | 15-950 | Poland |
| Research Site | Gdansk | 80-952 | Poland |
| Research Site | Grudziądz | 86-300 | Poland |
| Research Site | Koszalin | 75-581 | Poland |
| Research Site | Piotrkow Trybunalski | 97-300 | Poland |
| Research Site | Poznan | 61-731 | Poland |
| Research Site | Warsaw | 02-005 | Poland |
| Research Site | Warsaw | 02-781 | Poland |
| Research Site | Wroclaw | 50-556 | Poland |
| Research Site | Wroclaw | 53-413 | Poland |
| Research Site | Ivanovo | 153040 | Russia |
| Research Site | Krasnoyarsk | 660133 | Russia |
| Research Site | Moscow | 105077 | Russia |
| Research Site | Moscow | 115280 | Russia |
| Research Site | Moscow | 125367 | Russia |
| Research Site | Nizhny Novgorod | 603074 | Russia |
| Research Site | Obninsk | 249036 | Russia |
| Research Site | Omsk | 644013 | Russia |
| Research Site | Saint Petersburg | 191014 | Russia |
| Research Site | Saint Petersburg | 194017 | Russia |
| Research Site | Saint Petersburg | 194044 | Russia |
| Research Site | Saint Petersburg | 194354 | Russia |
| Research Site | Saint Petersburg | 195271 | Russia |
| Research Site | Saint Petersburg | 197758 | Russia |
| Research Site | Vologda | 160012 | Russia |
| Research Site | Yaroslavl | 150054 | Russia |
| Research Site | Badajoz | 06008 | Spain |
| Research Site | Barcelona | 08025 | Spain |
| Research Site | Barcelona | 08036 | Spain |
| Research Site | Barcelona | 08208 | Spain |
| Research Site | Barcelona | 8003 | Spain |
| Research Site | Elche(Alicante) | 03202 | Spain |
| Research Site | Madrid | 08035 | Spain |
| Research Site | Madrid | 28040 | Spain |
| Research Site | Madrid | 28041 | Spain |
| Research Site | Madrid | 28046 | Spain |
| Research Site | Málaga | 29010 | Spain |
| Research Site | Oviedo | 33011 | Spain |
| Research Site | Pamplona | 31008 | Spain |
| Research Site | Pozuelo de Alarcón | 28223 | Spain |
| Research Site | Seville | 41009 | Spain |
| Research Site | Seville | 41014 | Spain |
| Research Site | Valencia | 46014 | Spain |
| Research Site | Valencia | 46026 | Spain |
| Research Site | Birmingham | B15 2TH | United Kingdom |
| Research Site | Glasgow | G12 0YN | United Kingdom |
| Research Site | Guildford | CU2 7XX | United Kingdom |
| Research Site | London | E1 1BB | United Kingdom |
| Research Site | London | NW1 2PG | United Kingdom |
| Research Site | London | SE1 9RT | United Kingdom |
| Research Site | Sheffield | S10 2JF | United Kingdom |
| Research Site | Southampton | S016 6YD | United Kingdom |
| Research Site | Taunton | TA1 5DA | United Kingdom |
| ID | Term |
|---|---|
| D000093284 | Non-Muscle Invasive Bladder Neoplasms |
| ID | Term |
|---|---|
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D001749 | Urinary Bladder Neoplasms |
| D014571 | Urologic Neoplasms |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D001745 | Urinary Bladder Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000613593 | durvalumab |
| D001500 | BCG Vaccine |
| ID | Term |
|---|---|
| D032581 | Tuberculosis Vaccines |
| D001428 | Bacterial Vaccines |
| D014612 | Vaccines |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |
Not provided
Not provided